KDev Investments AB 4
4 · Aprea Therapeutics, Inc. · Filed Apr 15, 2020
Insider Transaction Report
Form 4
KDev Investments AB
10% Owner
Transactions
- Sale
Common Stock
2020-04-13$31.25/sh−210,548$6,579,625→ 2,234,289 total(indirect: See Footnote)
Footnotes (2)
- [F1]The amount of securities of Aprea Therapeutics, Inc. (the "Issuer") reported as beneficially owned includes shares held of record by: KDev Investments AB, Karolinska Development AB and KCIF Co-Investment Fund KB (collectively, the "Reporting Persons").
- [F2]Karolinska Development AB ("Karolinska") is the majority owner and co-manager of KDev Investments AB and a limited partner of KCIF Co-Investment Fund KB. Karolinska and each of the other Reporting Persons disclaim beneficial ownership of any shares of the Issuer's Common Stock owned of record by any of the other Reporting Persons except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that any such entity is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The address of each of (i) KDev Investments AB, (ii) Karolinska Development AB, and (iii) KCIF Co-Investment Fund KB is Tomtebodavagen 23A, SE 171 65 Solna, Sweden.